Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs New York Times Co (NYT) Price & Performance

Humana IncTrade
New York Times CoTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs New York Times Co — how do they compare? Humana Inc trades at $435.16 (market cap $46.49B), while New York Times Co trades at $66.4 (market cap $10.74B). The key difference: Humana Inc is far larger — about 4.3× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and New York Times Co for 81 Days on average.

HUMNYT
Market Cap
$46.49B$10.74B
Volume
2,567,7042,096,352
Sector
HealthMedia
52-Week High
$409.85$85.86
52-Week Low
$163.67$54.66
Typical Hold Time
51 Days81 Days
Enterprise Value
$53.84B$10.14B
Dividend Yield
0.91%1.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.

The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.

New York Times Co

The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.

Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HUM
93% Buy7% Sell
Avg holding period · 51 Days
NYT
13% Buy87% Sell
Avg holding period · 81 Days

Top news

Latest headlines on both assets

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT →